In 3 Months Since Launch in October 2022
Hanmi Pharmaceutical's U.S. partner Spectrum announced in a press release on Jan. 31 that sales of Rolvedon (product name in Korea: Rolontis), which was launched across the United States in October 2022, reached US$10 million in three months.
Spectrum said in the press release that 70 clients have purchased Rolvedon since its launch last year, adding that the top three community oncology networks, which account for 22 percent of the total clinic market, have begun utilizing Rolvedon.
Rolvedon was included in guidelines for febrile neutropenia prevention and treatment options recommended by the National Comprehensive Cancer Network (NCCN) in December 2022.
Spectrum plans to disclose its specific financial situations and various achievements with regard to Rolvedon in detail during an earnings announcement in March.